VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaki...
June 22 2020 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking
study showing that its proprietary MOSPD2 bi-specific antibody
candidates induced T-cell activation and significantly extended the
survival of animals carrying established metastatic cervical and
breast cancer (p=0.001; p=0.002). Data are presented today at the
American Association for Cancer Research (AACR) Virtual Annual
Meeting II, being held June 22–24, 2020.
"Identifying a tumor-specific target is a key step for
developing precise and safe immunotherapy for cancer, and MOSPD2
may be an ideal target. Our new data provide in-vitro and in-vivo
proof-of-concept for the potential of VBL's novel MOSPD2
bi-specific antibody candidates for immuno-oncology mediated
therapy for solid tumors," said Dror Harats, M.D., Chief Executive
Officer of VBL Therapeutics.
VBL's research has identified MOSPD2 as a protein involved in
cell motility, whose expression is highly elevated in various solid
tumors. The proprietary bi-specific antibody candidates developed
by VBL have two separate arms – one arm binds to MOSPD2 on tumor
cells and the second recruits host T-cells that attack the tumor.
The data presented today demonstrate that the company's bi-specific
antibody candidates: 1) mediated killing of tumor cells by CD8
T-cells in a dose-dependent manner; 2) induced T-cell activation
in-vivo; and 3) extended survival of tumor-bearing animals. The
results highlight the potential of MOSPD2-mediated immuno-oncology
therapy for the treatment of various solid tumors.
For VBL's poster presentations at AACR kindly see the following
links: LB-poster and Poster2
About VBL's VB-600 PlatformVBL is conducting
two parallel drug development programs that are exploring the
potential of MOSPD2 (motile sperm domain-containing protein 2), a
protein that VBL has identified as a key regulator of cell
motility, as a therapeutic target for inflammatory diseases and
cancer. Our VB-600 platform comprises classical anti-MOSPD2
investigational monoclonal antibodies for inflammatory indications,
as well as bi-specific antibody candidates for oncology.
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. VBL’s lead oncology product
candidate, ofranergene obadenovec (VB-111), is a first-in-class,
targeted anti-cancer gene-therapy agent that is being developed to
treat a wide range of solid tumors. It is conveniently administered
as an IV infusion once every two months. It has been observed to be
well-tolerated in >300 cancer patients and demonstrated activity
signals in a VBL-sponsored “all comers” phase 1 trial as well as in
three VBL-sponsored tumor-specific phase 2 studies. Ofranergene
obadenovec is currently being studied in a VBL-sponsored phase 3
potential registration trial for platinum-resistant ovarian
cancer.
Forward Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
may include, but are not limited to, statements regarding our
programs, including MOSPD2, including their clinical development,
therapeutic potential and clinical results and the impact of the
COVID-19 pandemic on our business, operations, clinical trials,
supply chain, strategy, goals and anticipated timelines and
clinical results. These forward-looking statements are not promises
or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ
materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the
risk that historical clinical trial results may not be predictive
of future trial results, that our financial resources do not last
for as long as anticipated, and that we may not realize the
expected benefits of our intellectual property protection. A
further list and description of these risks, uncertainties and
other risks can be found in our regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2019, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024